|
|
Anavex Screening Healthy Volunteers For Phase I, First-In-Human Clinical Study in Alzheimer's Disease
Sources News Release
http://www.sources.com/Releases/NR1214.htm
Publisher: Dr. Cameron Durrant, MD, MBA, Alzheimer's Disease and Pharmaceuticals/Biot
Date Written: 31/03/2011
Year Published: 2011
Resource Type: Article
Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) has announced screening of the first healthy volunteers for the Phase I clinical study of ANAVEX 2-73, its lead compound for the treatment of Alzheimer’s disease. ANAVEX 2-73 is the first of a new
Abstract: Hoboken, NJ – March 31, 2011 -- Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) today announced screening of the first healthy volunteers for the Phase I clinical study of ANAVEX 2-73, its lead compound for the treatment of Alzheimer’s disease. ANAVEX 2-73 is the first of a new class of wholly-owned, oral, disease-modifying compounds, which act through sigma-1 receptor agonism as well as muscarinic cholinergic effects and up-regulation of Bcl-2. ANAVEX 2-73 also modulates endoplasmic reticu...
To read the full release go to http://www.sources.com/Releases/NR1214.htm
Topics
|
AlterLinks
c/o Sources
© 2025.
|
|
|
|
